CD4 and cancer: Additionally, many antibody-based bispecific therapies bind to cancer surface antigens on-target cells rather than pHLA which will alter their mode of action, as, unlike pHLA, these antigens are unable to recruit CD4 and CD8 co-receptors, and so may display significantly different optima.